The relevance of ethnic influences on pharmacogenetics to the treatment of psychosis

Drug Metabolism and Drug Interactions

Volumn 16, Issue 1, 2000, Pages 15-38

  Aitchison, Katherine J ^a   Jordan, Barry D ^b   Sharma, Tonmoy ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b BURKE REHABILITATION HOSPITAL   (United States)

Author keywords

Antipsychotics; Cytochrome P450; Ethnicity; Metabolism; Pharmacogenetics

Indexed keywords

ANESTHETIC AGENT; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; CARDIAC AGENT; CIMETIDINE; CYTOCHROME P450; DRUG METABOLIZING ENZYME; IMMUNOSUPPRESSIVE AGENT; NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR; STEROID;

ARTICLE; DRUG METABOLISM; DRUG RESPONSE; ENZYME ACTIVITY; ENZYME METABOLISM; ETHNOLOGY; GENETIC VARIABILITY; HEREDITY; PHARMACOGENETICS; PSYCHOSIS;

EID: 0033967576     PISSN: 07925077     EISSN: None     Source Type: Journal    
DOI: 10.1515/DMDI.2000.16.1.15     Document Type: Article

References (97)

1. Vogel F. Moderne Probleme der Humangenetik. Ergebn Inn Med Kinderheuilk 1959; 12: 52-125.
2. Daly AK, Bröckmoller J, Broly F, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996; 6: 193-201.
3. Marez D, Legrand M, Sabbagh N, et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997; 7: 193-202.
4. Alvan G, Bechtel P, Iselius L, Gunder-Remy U. Hydroxylation polymorphisms of DB and mephenytoin in European populations. Eur J Clin Pharmacol 1990; 39: 533-537.
5. Woolhouse NM, Eichelbaum M, Oates NS, Idle JR, Smith R. Dissociation of co-regulatory control of debrisoquin/phenformin and SP oxidation in Ghanaians. Clin Pharmacol Ther 1985; 37: 512-521.
6. Llerena A, Herraiz AG, Cobaleda J, Johansson I, Dahl ML. DB and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents. Clin Pharmacol Ther 1993; 54: 606-611.
7. Masimirembwa C, Hasler J, Bertilsson L, Johansson I, Ekberg O, Ingelman-Sundberg M. Phenotype and genotype analysis of DB hydroxylase (CYP2D6) in a black Zimbabwean population: reduced enyzme activity and evaluation of metabolic correlation of CYP2D6 probe drugs. Eur J Clin Pharmacol 1996; 51: 117-122.
8. Leathart JBS, London SJ, Steward A, Adams JD, Idle JR, Daly AK. CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. Pharmacogenetics 1998; 8: 529-541.
9. Nakamura K, Goto F, Ray WA, et al. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985; 38: 402-408.
10. Lou YC, Liu Y, Bertilsson L, Sjöqvist F. Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet 1987; II: 852-853.
11. Horai Y, Nakano M, Ishizaki T, et al. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 1989; 46: 198-207.
12. Sohn D-R, Shin S-G, Park C-W, Kusaka M, Chiba K, Ishizaki T. Metoprolol oxidation polymorphism in a Korean population: comparison with native Japanese and Chinese populations. Br J Clin Pharmacol 1991; 32: 504-507.
13. Du YL, Lou YQ. Polymorphism of DB 4-hydroxylation and family studies of poor metabolizers in Chinese population. Acta Pharmacologica Sinica 1990; 11: 7-10.
14. Bertilsson L, Lou Y-Q, Du Y-L, et al. Pronounced differences between native Chinese and Swedish population in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992; 51: 388-397.
15. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjöqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P450D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for DB hydroxylation. Mol Pharmacol 1994; 46: 452-459.
16. Lee EJD, Jeyaseelan K. Frequency of human CYP2D6 mutant alleles in a normal Chinese population. Br J Clin Pharmacol 1994; 37: 605-607.
17. Masimirembwa C, Persson I, Bertilsson L, Hasler J, Ingelman-Sundberg M. A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished DB hydroxylase activity. Br J Clin Pharmacol 1996; 42: 13-719.
18. Droll K, Bruce-Mensah, Otton SV, Gaedigk A, Sellers EM, Tyndale RF. Comparison of three CYP2D6 probe substrates and genotpye in Ghanaians, Chinese and Caucasians. Pharmacogenetics 1998; 8: 325-333.
19. Dahl M-L, Yue Q-Y, Roh H-K, et al. Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects. Pharmacogenetics 1995; 5: 150-164.
20. Nowak MP, Tyndale RF, Sellers EM. CYP2D6 phenotype and genotype in a Canadian Native Indian population. Pharmacogenetics 1997; 7: 145-148.
21. MuUoz S, Vollrath V, Vallejos MP, et al. Genetic polymorphisms of CYP2D6, CYP1A1 and CYP2E1 in the South-Amerindian population of Chile. Pharmacogenetics 1998; 8: 343-351
22. Bailliet G, Rothammer F, Carnese FR, Bravi CM, Bianchi NO. Founder mitochondrial haplotypes in Amerindian populations. Am J Hum Genet 1994; 55: 27-33.
23. Price Evans DAP, Krahn P, Narayanan N. The mephenytoin (cytochrome P450 2C19) and dextromethorphan (cytchrome P450 2D6) polymorphisms in Saudi Arabians and Filipinos. Pharmacogenetics 1995; 5: 64-71.
24. Sommers De K, Moncrieff J, Avenant J. Non-correlation between DB and metoprolol polymorphisms in the Venda. Human Toxicol 1989; 8: 365-368.
25. Lennard MS, Iyun AO, Jackson PR, Tucker GT, Wood HF. Evidence for a dissociation of SP, DB and metoprolol metabolism in Nigerians. Pharmacogenetics 1992; 2: 89-92.
26. Simooya OO, Njunju E, Rostami Hodjegan A, Lennard MS, Tucker GT. DB and metoprolol oxidation in Zambians: a population study. Pharmacogenetics 1993; 3: 205-208.
27. Bathum L, Johansson I, Ingelman-Sundberg M, HorderM, Brøsen K. Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction. Pharmacogenetics 1998; 8: 119-123
28. Dahl M, Johansson I, Bertisson L, Ingelman-Sundberg M, Sjöqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995; 274: 516-520.
29. Sachse S, Bröckmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60: 284-295.
30. Masimirembwa CM, Johansson I, Hasler JA, Ingelman-Sundberg M. Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean population. Pharmacogenetics 1993; 3: 275-280.
31. Agundez JAG, Ledesma MC, Ladero JM, Benitez J. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther 1995; 57: 265-269.
32. McLellan RA, Oscarson M, Seidegard J, Evans DAP, Ingelman-Sundberg M. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics 1997; 7: 187-191.
33. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 1996; 278: 441-446
34. Dahl-Puustinen M-L, Liden A, Nordin AC, Bertilsson L. Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings. Clin Pharmacol Ther 1989; 46: 78-81.
35. Dahl M-L, Ekqvist B, Widén J, Bertilsson L. Disposition of the neuroleptic zuclopenthixol cosegrates with the polymorphic hydroxylation of debrisoquine in humans. Acta Psychiatr Scand 1991; 84: 99-102.
36. Jerling M, Dahl M-L, Åberg-Wistedt A, et al. The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenzaine and zuclopenthixol. Clin Pharmacol Ther 1996; 56: 423-428.
37. Lin KM, Poland RE. Ethnicitiy, culture, and psychopharmacology. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press Ltd., 1995; 1907-1917.
38. Aitchison KJ, Patel M, Taylor M, et al. Neuroleptic sensitivity and enzyme deficiency in two schizophrenic brothers: a case report. Schizophr Res 1995; 18: 140 (abst).
39. Gill M, Hawi A, Webb M. Homozygous mutation at cytochrome P4502D6 in an individual with schizophrenia: implications for antipsychotic drugs, side effects and compliance. Irish J Psychol Med 1997; 14: 38-39.
40. Armstrong M, Daly AK, Blennerhassett R, Ferrier N, Idle JR. Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype. Br J Psychiatry 1997; 170: 23-26.
41. Potkin SG, Shen T, Pardes H, et al. Haloperidol concentrations elevated in Chinese patients. Psychiatry Res 1984; 12: 167-172.
42. 2 dopoamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry 1995; 152: 173-178.
43. Suzuki A, Otani K, Mihara K, et al. Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients. Pharmacogenetics 1997; 7: 415-418.
44. Lin KM, Poland RE, Nuccio I, et al. A longitudinal assessment of haloperidol dosage and serum concentration in Asian and Caucasian schizophrenic patients. Am J Psychiat 1989; 146: 1307-1311.
45. Lin KM, Poland RE, Lau JK, Rubin RT. Haloperidol and prolactin concentrations in Asians and Caucasians. J Clin Psychopharmacol 1988; 8: 195-201.
46. Bertilsson L, Dahl M-L, Sjöqvist F, et al. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine [letter]. Lancet 1993; 341: 63.
47. Aitchison KJ, Munro J, Wright P, et al. Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation. Br J Clin Pharmacol, submitted.
48. Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry 1996; 57 (Suppl 11): 12-25.
49. Pirmohamed M, Williams D, Madden S, Templeton E, Park BK. Metabolism and bioactivation of clozapine by human liver in vitro. J Pharmacol Exp Ther 1995; 272: 984-990.
50. Arranz MJ, Dawson E, Shaikh S, et al. Cytochrome P4502D6 genotype does not determine response to clozapine. Br J Clin Pharmacol 1995; 39: 417-420.
51. Eiermann B, Engel G, Johansson I, Zanger UM, Bertilsson L. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol 1997; 44: 439-446.
52. Centorrino F, Baldessarini RJ, Frankenburg FR, Kando J, Volpicelli SA, Flood JG. Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am J Psychiatr 1996; 153: 820-822.
53. Ahsan CH, Renwick AG, Macklin B, Challenor VF, Waller DG, George CF. Ethnic differences in the pharmacokinetics of oral nifedipine. Br J Clin Pharmacol 1991; 31: 399-403.
54. Ahsan CH, Renwick AG, Waller DG, Challenor VF, George CF, Amanullah M. The influences of dose and ethnic origins on the pharmacokinetics of nifedipine. Clin Pharmacol Ther 1993; 54: 329-338.
55. Yue QY, Svensson JO, Aim C, Sjöqvist F, Säwe J. Interindividual and interethnic differences in the demethylation and glucornidation of codeine. Br J Clin Pharmacol 1989; 28: 629-637.
56. Yue Q-Y, Svensson J-O, Säwe J, Bertilsson L. Codeine metabolism in three Oriental populations: a pilot study in Chinese, Japanese and Koreans. Pharmacogenetics 1995; 5: 173-177.
57. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998; 90: 1225-1229.
58. Watkins PB. The CYP3A family: extrahepatic tissue distribution and role. Proceedings of the Twelfth International Symposium on Microsomes and Drug Oxidations, Montpellier, France, July 1998; PL2-3 [abst].
59. Pan LP, De Vriendt C, Belpaire FM. In-vitro characeterization of the cytochrome P450 isoenzymes involved in the back oxidation and N-dealkylation of reduced haloperidol. Pharmacogenetics 1998; 8: 383-389.
60. Fang J, Baker GB, Silverstone PH, Coutts RT. Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol. Cell Mol Neurobiol 1997; 17: 227-233.
61. Bareggi SR, Mauri M, Cavallaro R, Regazzetti MG, Moro AR. Factors affecting the clinical response to haloperidol therapy in schizophrenia. Clin Neuropharmacol 1990; 13 (Suppl 1): S29-S34.
62. Lane H-Y, Hu O Y-P, Jann MW, Deng H-C, Lin H-N, Chang W-H. Dextromethorphan phenotying and haloperidol disposition in schizophrenic patients. Psychiat Res 1997; 69: 105-111.
63. Aitchison KJ, Meehan K, Murray RM. Prescribing for a first episode of affective psychosis. In: First Episode Psychosis, London, UK: Martin Dunitz Ltd, 1999; 78.
64. Funderburg LG, Vertrees JE, True JE, et al. Seizure after the addition of erythromycin to clozapine treatment. Am J Psychiat 1994; 151: 1840-1841.
65. Le Marchand L, Franke AA, Custer L, Wilkens LR, Cooney RV. Lifestyle and nutritional correlates of cytochrome CYP1A2 activity: inverse associations with plasma lutein and alpha-tocopherol. Pharmacogenetics 1997; 7: 11-19.
66. Nakajima M, Yokoi T, Mizutani M, Shin S, Kadlubar FF, Kamataki T. Phenotyping of CYP1A2 in Japanese population by analysis of caffeiene urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene. Cancer Epidemiol Biomarkers Prev 1994; 3: 415-421.
67. Kalow W, Tang B-K. Use of caffeine metabolic ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther 1991; 50: 508-519.
68. Butler MA, Lang NP, Young JF, et al. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992; 2: 116-127.
69. Vistisen K, Poulsen HE, Loft S. Foreign compound metabolism capacity in man measured from metabolites for dietary caffeine. Carcinogenesis 1992; 13: 1561-1568.
70. Lang NP, Butler MA, Massengill J, et al. Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer or polyps. Cancer Epidemiol Biomarkers Prev 1994; 3: 675-682.
71. Relling MV, Lin J-S, Ayers GD, Evans WE. Racial and gender differences in N-acetyltransferase, xanthine oxidase. and CYP1A2 activities. Clin Pharmacol Ther 1992; 52: 643-658.
72. Horn EP, Tucker MA, Lambert G, et al. A study of gender-based cytochrome P4501A2 variability: a possible mechanism for the male excess of bladder cancer. Cancer Epidemiol Biomarkers Prev 1995; 4: 69-74.
73. Abernethy DR, Todd EL. Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives. Eur J Clin Pharmacol 1985; 28: 425-428.
74. Knutti R, Rothweler H, Schlatter CH. Effect of pregnancy on the pharmacokinetics of caffeine. Eur J Clin Pharmacol 1981; 21: 121-126.
75. Sinha R, Rothman N, Brown ED, et al. Panfried meat containing high levels of heterocyclic aromatic amines but low levels of polycyclic aromatic hydrocarbons induces cytochrome P4501A2 activity in humans. Cancer Res 1994; 54: 6154-6159.
76. Casley WL, Menzies JA, Mousseau N, Girard M, Moon TW, Whitehouse LW. Increased basal expression of hepatic CYP1A1 and CYP1A2 genes in inbred mice selected for susceptibiliby to acetaminophen-induced hepatotoxicity. Pharmacogenetics 1997; 7: 283-293.
77. Taylor D. Pharmacokinetic interactions involving clozapine. Br J Psychiat 1997; 171: 109-112.
78. Shader RI, Greenblatt DJ. Clozapine and fluvoxamine, a curious complexity. J Clin Psychopharmacol 1998; 18: 101-102.
79. Byerly MJ, DeVane CL. Pharmacokinetics of clozapine and risperidone: a review of recent literature. J Clin Psychopharmacol 1996; 16: 177-187.
80. Chang W-H, Chien C-P, Lin S-K, Chung M-C. Elevated plasma clozapine concentrations in Chinese patients. Neuropsychopharmacology 1993; 9 (Suppl 2): 117S-118S (abst).
81. Bender S, Eap CB. Very high cytochrome P4501A2 activity and nonresponse to clozapine. Arch Gen Psychiat 1998; 55: 1048-1049.
82. Goldstein JA, de Morais SMF. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994; 4: 285-299.
83. Bertilsson L, Dahl M-L. Polymorphic drug oxidation. Relevance to the treatment of psychiatric disorders. CNS Drugs 1996; 5: 200-223.
84. m diazepam N-demethylases. Drug Metab Dispos 1997; 25: 133-139.
85. Krecic ME, Shepard DR, Chang TH, Colliins J, Gerber N. Stereoselective metabolism of phenytoin by hepatic microsomes and human CYP2C9 and CYP2C18 expressed in yeast. ISSX Proc 1995; 8: 370.
86. Bajpai M, Roscos LK, Shen DD, Levy RH. Roles of cytochrome P450 2C19 in the Stereoselective metabolism of phenytoin to its major metabolite. Drug Metab Dispos 1996; 24: 1401-1403.
87. Karam WG, Goldstein JA, Lasker JM, Ghanayem BI. Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metab Dispos 1996; 24: 1081-1087.
88. Mamiya K, Ieiri I, Miyahara S, Imai J, Furuumi H, Fukumaki Y, Ninomiya H, Tashiro N, Yamada H, Higuchi S. Association of polymorphisms in the cytochrome P450 (CYP) 2C19 and 2C18 genes in Japanese epileptic patients. Pharmacogenetics 1998; 8: 87-90.
89. Hashimoto Y, Otsuki Y, Odani A, Takano M, Hattori H, Furusho K, Inui K-I. Effect of CYP2C polymorphisms on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Biol Pharm Bull 1996; 19: 1103-1105.
90. Wang S-L, Huang J-D, Lai M-D, Tsai J-J. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 1995; 5: 37-42.
91. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995; 29: 192-209.
92. Persson I, Aklillu E, Rodrigues F, Bertilsson L, Ingelman-Sundberg M. S-Mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians. Pharmacogenetics 1996; 6: 521-526.
93. Goldstein JA. Polymorphisms in human CYP2C19. Proceedings of the Twelfth International Symposium on Microsomes and Drug Oxidations. Montpellier, France, July 1998; S10-13 [abst].
94. Schmider J, Greenblatt DJ, von Moltke LL, Shader RI. Relationship of in vitro data on drug metabolism to in vivo pharmacokinetics and drug interactions: implications for diazepam disposition in humans. J Clin Psychopharmacol 1996; 16: 267-272.
95. Kumana CR, Lauder IJ, Chan M, et al. Differences in diazepam pharmacokinetics in Chinese and white Caucasians - relation to body lipid stores. Eur J Clin Pharmacol 1987; 32: 211-215.
96. Andersson T. Pharmcokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996; 31: 9-28.
97. Rojas M, Alexandrov K, Cascorbi I, Brockmoller J, Likhachev A, Pozharisski K, Bouvier G, Auburtin G, Mayer L, Kopp-Schneider A, Roots I, Bartsch H. High benzo[a]pyrene diol-epoxide DNA adduct levels in lung and blood cells from individuals with combined CYP1A1 MspI/MspI-GSTM1 *0/*0 genotypes. Pharmacogenetics 1998; 8: 109-118.